Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Expression of Serpin B9 as a Prognostic Factor of Colorectal Cancer

ONDREJ VYCITAL, PAVEL PITULE, PETR HOSEK, TOMAS KRIZ, VLADISLAV TRESKA and VACLAV LISKA
Anticancer Research November 2019, 39 (11) 6063-6066; DOI: https://doi.org/10.21873/anticanres.13813
ONDREJ VYCITAL
1Department of Surgery, Charles University, University Hospital Pilsen, Pilsen, Czech Republic
2Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: vycitalo@fnplzen.cz
PAVEL PITULE
2Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PETR HOSEK
2Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMAS KRIZ
2Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VLADISLAV TRESKA
1Department of Surgery, Charles University, University Hospital Pilsen, Pilsen, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VACLAV LISKA
1Department of Surgery, Charles University, University Hospital Pilsen, Pilsen, Czech Republic
2Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Treatment of colorectal cancer (CRC) does not reflect immune interactions between tumours and macro-organisms. Serpin B9 is known as an inhibitor of Granzyme B. The aim of this study was to evaluate the impact of the expression of Serpin B9 in CRC and healthy colon tissue on prognosis. Patients and Methods: This retrospective study included 74 CRC patients in all stages. Analysis of gene expression was performed with quantitative polymerase chain reaction with reverse transcription using specific primers and master mix Xceed qPCR SG. Expression was normalized to the reference genes GAPDH, ACTB, and PSMC. Results: Increased expression of Serpin B9 in healthy tissue was significantly associated with longer overall survival (OS). This association was found both in all patients and in the group of patients with distant metastases. Conclusion: The presented results support previous evidence of positive influence of the interaction between immune system and tumour on the prognosis of CRC.

  • Colorectal cancer
  • visceral surgery
  • immunosurveillance
  • serpin B9
  • prognostic factor

Colorectal carcinoma (CRC) is a severe health and social issue occurring at high incidence rates (1). Recent approaches to treatment of CRC are based on the staging according to the Union Internationale Contre le Cancer (UICC), which integrates the TNM classification with other risk factors. However, these risk factors do not reflect immune interactions between tumours and macro-organisms (2).

Serpin B9 is known as an endogenous inhibitor of Granzyme B in humans, which protects against the cytotoxic granule leakage. At the molecular level, Serpin B9 inhibits the cytolytic function of Granzyme B by forming a reversible Michaelis complex (3). Serpin B9 is secreted from cytotoxic lymphocytes (4), smooth muscle cells, endothelial cells, and hepatocytes. Immunoprivileged cells, i.e., trophoblast cells, Sertoli cells, granulosa cells and cells of the eye lens produce this inhibitor as well. The proposed function of Serpin B9 is the protection against cytotoxic immunity (5). In malignant cells, Serpin B9 production has been observed in breast cell carcinoma (6), melanomas (7), cervical cancer (8) and in leukemia cells (9). In addition, CRC cells also produce Serpin B9 (8). Expression of Serpin B9 is one of the ways by which malignant cells avoid cytotoxic lymphocyte-mediated killing (10). Serpin B9 expression in rectal cancer tissue has been suggested as a negative predictive factor of neoadjuvant chemoradiotherapy (11, 12).

We have previously shown that increased expression of Serpin B9 in colorectal cancer cells is associated with regional lymph node metastases (13).

The aim of the present study was to evaluate the impact of Serpin B9 expression in CRC and healthy colon tissue on the progression and prognosis of CRC. The secondary target of this study was to confirm previous results showing that increased expression of Serpin B9 in colorectal cancer cells is associated with regional lymph node metastases.

Patients and Methods

Patients. This monocentric retrospective study included 74 CRC patients, 10 patients were in stage I, 20 patients in stage II, 35 patients in stage III and 9 patients in stage IV. This study was conducted at the Department of Surgery, Charles University, Medical School and Teaching Hospital Pilsen between 2013 and 2016. A total of 36 females (median age 68.86 years, min 49.27 and max 89.81 years) and 38 males (median age 67.36 years, min 38.74 and 88.14 years), who underwent surgical therapy for CRC were included in the study. Exclusion criteria were: inflammatory bowel disease, familiar adenomatosis, insufficient number of examined lymph nodes in resected bowel or rectum (less than 13) and or previous malignancy. Patients presenting tumour rupture, acute bleeding and ileus were also not included. The follow-up of patients occurred during standard dispensarization.

Statistics. Differences in the expression of serpin B9 between healthy tissue and tumour were analysed using Wilcoxon signed-rank test. Mann-Whitney U-test was used to compare Serpin B9 expression (in healthy and tumour tissue) between patients with and without regional lymph node metastasis. Differences in Serpin B9 expression between UICC stages were assessed using Kruskal-Wallis ANOVA. The association between Serpin B9 expression and overall survival (OS) or disease-free interval (DFI) was investigated using univariable Cox proportional hazards model with subsequent stratification by median expression and visualisation by Kaplan–Meier plots. The analysis was performed using STATISTICA software (version 12, Cz, StatSoft, Inc. 2013, Prague, Czech Republic).

Gene expression analysis

Primer design. Oligonucleotide primers for quantitative real-time polymerase chain reaction (qPCR) were designed using Primer-3 software (14). All primers span exon-exon boundaries and their specificity was tested in silico by BLAST (15). Reference genes GAPDH, ACTB and PSMC4 were previously tested in our laboratory and were used for normalization of Serpin B9 expression. Optimal annealing temperature and specificity of reactions were evaluated by Cq values analysis, melt curve analysis and agarose gel electrophoresis.

RNA isolation. Snap-frozen samples of tumor tissue and macroscopically non-malignant mucosa were grounded in liquid nitrogen and total RNA was isolated by TRI Reagent®RT (Molecular Research Center, Inc., Cincinnati, OH, USA) according to manufacturer's protocol. RNA was resuspended in nuclease-free water and stored at −80°C. RNA concentration (absorbance at 260 nm) and purity (230 nm/260 nm absorbance ratio) were measured with the Tecan Infinite M200 (Tecan Trading AG, Männedorf, Switzerland) using NanoQuant settings. RNA integrity was examined by agarose gel electrophoresis.

Reverse transcription. Reverse transcription of RNA was performed using the RevertAid First Strand cDNA Synthesis Kit (ThermoFisher Scientific, Waltham, USA) in 20 μl reaction. Five hundred ng of total RNA were first treated for 5 min with DNase I (Top-Bio, Vestec, Czech Republic) to remove potential traces of genomic DNA. Mixture of random hexamers and oligo(dT)18 primers, each at a 2.5 μM final concentration, were used for reverse transcription. Reaction conditions were set according to the manufacturer's protocol. The quality of cDNA and the possibility of DNA contamination were examined by PCR in the absence of reverse transcriptase or cDNA samples (GAPDH primers, 40 cycles) and agarose gel electrophoresis.

Quantitative real-time PCR. Xceed qPCR SG master mix (IAB, Prague, Czech Republic) was used for qPCR. cDNA was diluted to 0.5 ng/μl and 4.75 μl of cDNA was mixed with 0.25 μl of gene specific primers and 5 μl of master mix in a final volume of 10 μl per reaction. Reference genes were analyzed in duplicate and Serpin B9 in triplicate using the CFX96 real-time PCR instrument (Biorad, Hercules, CA, USA). The following reaction conditions were used: initial denaturation at 95°C for 5 min, 45 two-step cycles with denaturation at 95°C for 10 sec and annealing and extension at 62°C for 30 sec, and finally melting curve analysis with denaturation at 95°C for 15 sec followed by continuous measurement of fluorescence between 60°C and 90°C with the step of 0.5°C. Data were analyzed using Biorad CFX Manager™ software and quality checked Cq values were used for statistical analysis.

Results

No significant differences were found in the expression of Serpin B9 between healthy and tumorous tissues (Figure 1). There were also no significant differences in Serpin B9 expression between groups UICC I, II, II and IV (Figure 2). Spearman test showed a non-significant perceptible trend in the expression of Serpin B9 in tumorous tissue with increasing UICC stage (p=0.075). We did not find any significant differences between groups of patients with and without metastases in regional lymph nodes (N0 versus N1 and N2 lymph node status).

Increased expression of Serpin B9 in healthy tissue was significantly associated with longer OS in all patients (p=0.0023, Figure 3), as well as in the group of patients with distant metastases (p=0.0169, Figure 4). Regarding DFI, no relationship between disease progression and Serpin B9 expression in either healthy or tumour tissue was observed.

Discussion

Based on the previous results of our immunohistochemical study in CRC (13), an increased Serpin B9 expression was expected to be found in the tumour tissue of UICC III (with lymph node metastasis) patients in comparison with tumour tissues of group UICC II (without lymph node metastasis). Surprisingly, this was not the case, probably because a whole spectrum of cells from the tumour tissue were analysed together in the expression assay, and not only adenocarcinoma cells. It is known that tumour infiltrating lymphocytes produce Serpin B9 (4). The presence of tumour infiltrating lymphocytes has been revealed to be an important prognostic factor (16, 17) that could influence the results. It remains unclear if there is any causality in the association of Serpin B9 expression in non-tumorous colon tissue and OS. Information from non-tumorous tissue samples can indicate its suitability and its impact on prognosis (18).

Because we showed significantly increased expression of Serpin B9 in non-tumorous tissue in the group of patients with distant metastases and better OS, it would be interesting to investigate the predictive value of serpin B9 expression in non -tumorous tissue on the effect of oncological treatment. Currently, there are data only about the influence of Serpin B9 expression in rectal cancer cells on the response to neoadjuvant chemoradiotherapy (11, 12). We did not evaluate expression of serpin B9 as a predictive factor of oncological treatment outcomes because of the small number of patients in the UICC IV group with increased expression of Serpin B9 (9 patients in the whole group).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

No significant differences were found in Serpin B9 expression between healthy and tumorous tissues.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

No significant differences in Serpin B9 expression were observed between the cohorts UICC I, UICC II, UICC III and UICC IV in tumorous tissue.

Conclusion

The present results support previous evidence indicating a positive influence of the interaction between immune system and tumor on the prognosis of CRC as exemplified by the effect of the expression of granzyme B inhibor – Serpin B9. On the other hand, the mechanism by which Serpin B9 influences the prognosis of CRC remains unclear. However, there is a plethora of prognostic factors available for CRC and it is now important to analyze them in order to select patients who will benefit from intensive oncological treatment.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Positive effect of increased Serpin B9 expression in healthy tissue on OS of all patients in the study.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Positive effect of increased Serpin B9 expression in healthy tissue on OS in the group of patients with distant metastases.

Acknowledgements

Funding: This study was supported by the National Sustainability Program I (NPU I; No. LO1503) provided by the Ministry of Education, Youth and Sports of the Czech Republic and by Grant Agency of the Czech Republic (GACR 18-09709S) and by Charles University Research Centre program UNCE/MED/006 “University Center of Clinical and Experimental Liver Surgery”.

Footnotes

  • Authors' Contributions

    Ondrej Vycital – corresponding author, methodology, data and specimen collection, data analysis, data curation, writing – original draft; Pavel Pitule – gene expression analysis; Tomas Kriz – data collection; Hosek Petr – data analysis, data curation, performance of the statistical analysis; Liskav Vaclav - supervision, validation, investigation; Treska Vladislav – supervision, validation.

  • Conflicts of Interest

    The Authors dcclare no conflicts of interest regarding this study.

  • Received September 5, 2019.
  • Revision received September 24, 2019.
  • Accepted September 30, 2019.
  • Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Ferlay J,
    2. Soerjomataram I,
    3. Dikshit R,
    4. Eser S,
    5. Mathers C,
    6. Rebelo M,
    7. Parkin DM,
    8. Forman D,
    9. Bray F
    : Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5), 2015. PMID: 25220842. DOI: 10.1002/ijc.29210
  2. ↵
    1. Sobin LH,
    2. Gospodarowicz MK,
    3. Wittekind CH
    : TNM classification of malignant tumours. 7th ed: Hoboken, NJ: Wiley-Blackwell, 2010. PMID: 20593484. DOI: 10.1002/path.2729
  3. ↵
    1. Losasso V,
    2. Schiffer S,
    3. Barth S,
    4. Carloni P
    : Design of human granzyme B variants resistant to serpin B9. Proteins 80(11): 2514-2522, 2012. PMID: 22733450. DOI: 10.1002/prot.24133
    OpenUrlCrossRefPubMed
  4. ↵
    1. Sun J,
    2. Bird CH,
    3. Sutton V,
    4. McDonald L,
    5. Coughlin PB,
    6. De Jong TA,
    7. Trapani JA,
    8. Bird PI
    : A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem 271(44): 27802-27809, 1996. PMID: 8910377. DOI: 10.1074/jbc.271.44.27802
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Bladergroen BA,
    2. Strik MC,
    3. Bovenschen N,
    4. van Berkum O,
    5. Scheffer GL,
    6. Meijer CJ,
    7. Hack CE,
    8. Kummer JA
    :The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. J Immunol 5: 3218-3225, 2001. PMID: 11207275. DOI: 10.4049/jimmunol.166.5.3218
    OpenUrl
  6. ↵
    1. Lauricella M,
    2. Carlisi D,
    3. Giuliano M,
    4. Calvaruso G,
    5. Cernigliaro C,
    6. Vento R,
    7. D'Anneo A
    : The analysis of estrogen receptor-α positive breast cancer stem-like cells unveils a high expression of the serpin proteinase inhibitor PI-9: Possible regulatory mechanisms. Int J Oncol 49(1): 352-360, 2016. PMID: 27121069. DOI: 10.3892/ijo.2016.3495
    OpenUrlPubMed
  7. ↵
    1. Irmler M,
    2. Thome M,
    3. Hahne M,
    4. Schneider P,
    5. Hofmann K,
    6. Steiner V,
    7. Bodmer JL,
    8. Schröter M,
    9. Burns K,
    10. Mattmann C,
    11. Rimoldi D,
    12. French LE,
    13. Tschopp J
    : Inhibition of death receptor signals by cellular FLIP. Nature 388(6638): 190-195, 1997. PMID: 9217161. DOI: 10.1038/40657
    OpenUrlCrossRefPubMed
  8. ↵
    1. Medema JP,
    2. de Jong J,
    3. Peltenburg LT,
    4. Verdegaal EM,
    5. Gorter A,
    6. Bres SA,
    7. Franken KL,
    8. Hahne M,
    9. Albar JP,
    10. Melief CJ,
    11. Offringa R
    : Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Nat Acad Sci 20: 11515-11520, 2001. PMID: 1156248. DOI: 10.1073/pnas.201398198
    OpenUrl
  9. ↵
    1. Fritsch K,
    2. Finke J,
    3. Grüllich C
    : Suppression of granzyme B activity and caspase-3 activation in leukaemia cells constitutively expressing the protease inhibitor 9: Ann Hematol Dec 92(12): 1603-1609, 2013. PMID: 23892923. DOI: 10.1007/s00277-013-1846-6
    OpenUrlPubMed
  10. ↵
    1. de Koning PJ,
    2. Kummer JA,
    3. de Poot SA,
    4. Quadir R,
    5. Broekhuizen R,
    6. McGettrick AF,
    7. Higgins WJ,
    8. Devreese B,
    9. Worrall DM,
    10. Bovenschen N
    : Intracellular serine protease inhibitor SERPINB4 inhibits granzyme M-induced cell death. PLoS One 6(8): e22645, 2011. PMID: 21857942. DOI: 10.1371/journal.pone.0022645
    OpenUrlCrossRefPubMed
  11. ↵
    1. Repetto O,
    2. De Re V,
    3. De Paoli A,
    4. Belluco C,
    5. Alessandrini L,
    6. Canzonieri V,
    7. Cannizzaro R
    : Identification of protein clusters predictive of tumor response in rectal cancer patients receiving neoadjuvant chemo-radiotherapy. Oncotarget 8(17): 28328-28341, 2017. PMID: 28423701. DOI: 10.18632/oncotarget.16053
    OpenUrlCrossRefPubMed
  12. ↵
    1. Chauvin A,
    2. Boisvert FM
    : Clinical proteomics in colorectal cancer, a promising tool for improving personalised medicine. Proteomes 6(4), 2018. PMID: 30513835. DOI: 10.3390/proteomes6040049
  13. ↵
    1. Vycital O,
    2. Dubova M,
    3. Palek R,
    4. Hosek P,
    5. Branzovsky J,
    6. Treska V,
    7. Daum O,
    8. Liska V
    : The impact of immune interaction on the metastatic infiltration of colorectal carcinoma to lymph nodes. Anticancer Res 38(7): 4159-4167, 2018. PMID: 29970545. DOI: 10.21873/anticanres.12709
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Untergasser A,
    2. Cutcutache I,
    3. Koressaar T,
    4. Ye J,
    5. Faircloth BC,
    6. Remm M,
    7. Rozen SG
    : Primer 3-new capabilities and interfaces. Nucleic Acids Res 40(15), 2012. PMID: 22730293. DOI: 10.1093/nar/gks596
  15. ↵
    1. Altschul SF,
    2. Madden TL,
    3. Schäffer AA,
    4. Zhang J,
    5. Zhang Z,
    6. Miller W,
    7. Lipman DJ
    : Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25(17): 3389-3402, 1997. PMID: 9254694. DOI: 10.1093/nar/25.17.3389
    OpenUrlCrossRefPubMed
  16. ↵
    1. Liska V,
    2. Vycital O,
    3. Daum O,
    4. Novak P,
    5. Treska V,
    6. Bruha J,
    7. Pitule P,
    8. Holubec L
    : Infiltration of colorectal carcinoma by S100+ dendritic cells and CD57+ lymphocytes as independent prognostic factors after radical surgical treatment. Anticancer Res 5: 2129-2132, 2012. PMID: 22593500.
    OpenUrl
  17. ↵
    1. Galon J,
    2. Costes A,
    3. Sanchez-Cabo F,
    4. Kirilovsky A,
    5. Mlecnik B,
    6. Lagorce-Pagès C,
    7. Tosolini M,
    8. Camus M,
    9. Berger A,
    10. Wind P,
    11. Zinzindohoué F,
    12. Bruneval P,
    13. Cugnenc PH,
    14. Trajanoski Z,
    15. Fridman WH,
    16. Pagès F
    : Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795): 1960-1964, 2006. PMID: 17008531. DOI: 10.1126/science.1129139
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Thiele JA,
    2. Hosek P,
    3. Kralovcova E,
    4. Ostasov P,
    5. Liska V,
    6. Bruha J,
    7. Vycital O,
    8. Rosendorf J,
    9. Opattova A,
    10. Horak J,
    11. Kralickova M,
    12. Vodicka P,
    13. Pitule P
    : lncRNAs in non-malignant tissue have prognostic value in colorectal cancer. Int J Mol Sci Sep 19(9): 2672, 2018. PMID: 30205577. DOI: 10.3390/ijms19092672
    OpenUrl
PreviousNext
Back to top

In this issue

Anticancer Research: 39 (11)
Anticancer Research
Vol. 39, Issue 11
November 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Expression of Serpin B9 as a Prognostic Factor of Colorectal Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
17 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Expression of Serpin B9 as a Prognostic Factor of Colorectal Cancer
ONDREJ VYCITAL, PAVEL PITULE, PETR HOSEK, TOMAS KRIZ, VLADISLAV TRESKA, VACLAV LISKA
Anticancer Research Nov 2019, 39 (11) 6063-6066; DOI: 10.21873/anticanres.13813

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Expression of Serpin B9 as a Prognostic Factor of Colorectal Cancer
ONDREJ VYCITAL, PAVEL PITULE, PETR HOSEK, TOMAS KRIZ, VLADISLAV TRESKA, VACLAV LISKA
Anticancer Research Nov 2019, 39 (11) 6063-6066; DOI: 10.21873/anticanres.13813
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Clinical Significance of Stanniocalcin2 mRNA Expression in Patients With Colorectal Cancer
  • Investigation of the underlying hub genes and molexular pathogensis in gastric cancer by integrated bioinformatic analyses
  • Google Scholar

More in this TOC Section

  • C-myc Oncogene Numerical Imbalances Analysis in Laryngeal Squamous Cell Carcinoma
  • Association of Interleukin-12A Genotypes With Nasopharyngeal Carcinoma Risk
  • Immunogenicity of Neoantigens in Colorectal Cancer: Potential Influence of Tumor Mutation Burden, Stages, and Metastasis
Show more Experimental Studies

Similar Articles

Keywords

  • colorectal cancer
  • visceral surgery
  • immunosurveillance
  • Serpin B9
  • prognostic factor
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire